Table 3 Cases of neural tube defects by monotherapy drug group
DrugNTDs in PCFA group (n (%) (95% CI))NTDs in no PCFA group (n (%) (95% CI))
CBZ3 (0.5) (0.0–1.5)0 (0.0) (0.0–0.8)
LTG1 (0.2) (0.0–0.9)0 (0.0) (0.0–1.1)
VPA3 (0.8) (0.3–2.2)7 (1.7) (0.7–3.4)
  • CBZ, carbamazepine; LTG, lamotrigine; NTD, neural tube defect; PCFA, preconceptual folic acid; VPA, sodium valproate.